Can bempedoic acid be co‑administered with a statin, and what is the recommended dosage?

Bempedoic Acid Co-Administration with Statins and Ezetimibe

Yes, bempedoic acid can be safely co-administered with statins and ezetimibe, with the standard dose being 180 mg orally once daily, though specific dose limitations apply for simvastatin (≤20 mg daily) and pravastatin (≤40 mg daily). 1

FDA-Approved Indication and Dosing

Bempedoic acid is FDA-approved as an adjunct to diet and maximally tolerated statin therapy for lowering LDL-C in adults with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). 1

Standard Dosing Regimen

• Dose: 180 mg orally once daily, with or without food 1
• Can be administered as monotherapy or in combination with statins and/or ezetimibe 1

Fixed-Dose Combination Option

• Bempedoic acid 180 mg/ezetimibe 10 mg: Available as a single tablet taken once daily 1
• This combination should be taken either 2 hours before or 4 hours after bile acid sequestrants if used together 1

LDL-C Reduction Efficacy

The lipid-lowering effect varies based on background therapy:

• Monotherapy: Approximately 24.5% LDL-C reduction 1, 2
• Added to statin therapy: Additional 15-18% LDL-C reduction (placebo-corrected) 1
• Fixed combination with ezetimibe on statin background: Additional 38% LDL-C reduction 1

Critical Drug-Drug Interactions with Statins

Avoid concomitant use of simvastatin >20 mg daily or pravastatin >40 mg daily when prescribing bempedoic acid. 1

Pharmacokinetic Interactions

Bempedoic acid increases statin exposure through OATP1B1 and OATP1B3 inhibition:

• Simvastatin: Approximately 2-fold increase in simvastatin acid AUC and 1.5-fold increase in Cmax 3
• Pravastatin: 2-fold increase in both AUC and Cmax 3, 4
• Atorvastatin and rosuvastatin: 1.7-fold increase in AUC, but within acceptable ranges and no dose adjustment required 3

A recent 2025 study demonstrated that staggered administration (versus simultaneous) does not mitigate the drug interaction between bempedoic acid and pravastatin, with pravastatin exposure increasing by 80% regardless of timing. 4

Combination with Ezetimibe

Bempedoic acid can be safely combined with ezetimibe with minimal pharmacokinetic interaction:

• Ezetimibe AUC and Cmax increase by less than 20% 3
• Total ezetimibe (including glucuronide) increases approximately 1.6-1.8-fold, which is not clinically meaningful 3
• No dose adjustment required 3

Clinical Application Algorithm

For Patients on Statin Therapy Requiring Additional LDL-C Lowering:

1. If on atorvastatin or rosuvastatin: Add bempedoic acid 180 mg daily without statin dose adjustment 1, 5

2. If on simvastatin >20 mg or pravastatin >40 mg: Either:

   • Reduce simvastatin to ≤20 mg or pravastatin to ≤40 mg before adding bempedoic acid 1
   • Switch to atorvastatin or rosuvastatin, then add bempedoic acid 6

3. If already on statin + ezetimibe: Consider adding bempedoic acid 180 mg (triple therapy) for additional 15-18% LDL-C reduction 1, 5, or use the fixed-dose combination of bempedoic acid/ezetimibe 6

For Statin-Intolerant Patients:

• Bempedoic acid 180 mg as monotherapy reduces LDL-C by approximately 24.5% 1, 2
• Bempedoic acid/ezetimibe fixed combination provides approximately 38-40% LDL-C reduction without statin 1, 2
• Bempedoic acid is activated only in the liver (not muscle), reducing myopathy risk 1, 2

Safety Considerations and Monitoring

Key Warnings:

• Hyperuricemia: Monitor uric acid levels before initiation and if symptoms develop; treat with urate-lowering drugs as needed 1
• Tendon rupture: Discontinue immediately if tendon rupture occurs; consider discontinuation for tendinitis symptoms 1
• Elevated liver enzymes: Monitor as clinically indicated 1

Metabolic Benefits:

• No increased diabetes risk unlike statins; may modestly improve glycemic profile 2, 7
• In the CLEAR Outcomes trial, new-onset diabetes occurred in 11.1% with bempedoic acid versus 11.5% with placebo (HR 0.95) 7

Cardiovascular Outcomes Evidence

The CLEAR Outcomes trial (completed 2022) demonstrated:

• 13% relative risk reduction in MACE-4 (cardiovascular death, nonfatal MI, nonfatal stroke, or coronary revascularization) in statin-intolerant patients 8, 9
• 30% risk reduction when analyzing only patients at high cardiovascular risk 8
• Absolute risk reduction of 2.4% in patients with diabetes 7

Common Pitfalls to Avoid

1. Do not exceed simvastatin 20 mg or pravastatin 40 mg when co-administering with bempedoic acid due to significant pharmacokinetic interactions 1, 3

2. Do not attempt staggered dosing to avoid drug interactions—this strategy is ineffective based on recent evidence 4

3. Do not discontinue therapy if very low LDL-C levels are achieved—maintain treatment if well-tolerated for sustained cardiovascular benefit 6

4. Monitor for tendon-related symptoms particularly in patients with history of tendon disorders 1